Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. While several peptide and protein biomarkers in cerebrospinal fluid (CSF) have been used for AD diagnosis, an unequivocal diagnosis in the early phases of AD is still lacking.

To ensure the safety and efficacy of LNP-based drugs, comprehensive characterization of these sophisticated molecules–the lipids and the genetic cargo–is paramount.

Unearthing novel drug targets with robust data support and a deep understanding of biological processes remains a pivotal challenge in drug discovery. In this engaging webinar, distinguished speakers Aaron Mitchell and Rasmus Wernersson from ZS Associates will unveil a comprehensive method that significantly enhances target prediction performance through the integration of multiomics data, coupled with a data-driven, cell-type specific network biology approach.

This exclusive Q&A event invites you to ask anything about the world of predatory conferences to our expert speaker.

In this webinar, you’ll hear how automated liquid handling for LC-MS/MS sample preparation contributed to the identification and quantification of over 30 metabolites that can predict adverse pregnancy outcomes, including pre-eclampsia.

In this webinar, our speaker will discuss the role of glucosyl and galactosyl ceramides as biomarkers and how their misregulation can be an identifier for various disease states including, but not limited to, Parkinson’s, Krabbe and Gaucher diseases.